ALK and inflammatory myofibroblastic tumor: This results in prolonged survival of the cancer cell, hyperproliferation and enhanced cell migration.[1,20–24] In contrast, actionable genomic alterations are not found in around 50% of IMT samples that are immunohistochemically negative for ALK.